

Tentative PROGRAM

Wednesday, October 30, 2024

13:30–14:15 Arrival and registration

14:15–14:30 WELCOME by CBMR Executive Director Professor **Juleen R. Zierath**

SESSION 1 CARDIOMETABOLIC INNOVATION: BRIDGING GAPS, SEIZING OPPORTUNITIES

14:30–15:00 [Title]

Richard DiMarchi, Professor, Indiana University Bloomington, USA

15:00–15:30 [Title]

John Wilding, Professor, University of Liverpool

15:30–15:45 BREAK

15:45–16:15 [Title]

Anne Tybjærg-Hansen, Clinical Professor, University of Copenhagen, DK

16:15–16:45 [Title]

Matthew Coghlan, Associate Vice President, Head Incretin Portfolio Science, Eli Lilly, UK

16:45–17:15 [Title]

Mads Krogsgaard Thomsen, CEO Novo Nordisk Foundation, DK

17:15–17:30 BREAK

17:30–18:00 **PANEL DISCUSSION 1**

18:00–19:00 BREAK

19:00 **SPEAKERS' DINNER**

Thursday, October 31, 2024

09:00–09:15 Welcome by CBMR Vice Executive Director Professor **Kei Sakamoto**

SESSION 2 INNOVATIVE VENTURES IN CARDIOMETABOLIC DISEASE THERAPEUTICS:
SCALING SUCCESS IN DRUG DEVELOPMENT ENTERPRISES

- 09:15–09:45 [Title]
Anders Hinsby, COO, Muna Therapeutics, DK
- 09:45–10:15 [Title]
Ashley Zehnder, Co-founder and Chief Executive Officer of Fauna Bio
- 10:15–10:30 **BREAK**
- 10:30–11:00 [Title]
Niels Vrang, CSO and co-founder GUBRA, DK
- 11:00–11:30 [Title]
Nancy Thornberry, Founding CEO and chair, Kallyope, USA
- 11:30–12:00 **PANEL DISCUSSION II**
- 12:00–13:00 **LUNCH**

SESSION 3 ENTREPRENEURIAL JOURNEYS: NAVIGATING THE PATH FROM ACADEMIC
DISCOVERY TO CLINICAL APPLICATION

- 13:00–13:15 **Session opening**
- 13:15–13:45 [Title]
Feng Zhang, Professor, Broad Institute of MIT and Harvard, USA
- 13:45–14:15 [Title]
Jan GJ van de Winkel, President and CEO, Genmab, DK
- 14:15–14:45 [Title]
Jens B Nielsen, CEO Bio Innovation Institute, DK
- 14:45–15:15 **BREAK**
- 15:15–15:45 [Title]
Jørgen Søberg Petersen, Senior Partner, Novo Holdings, DK
Johan Kördel, Managing Partner, Sound Bioventures, DK
- 15:45–16:15 **PANEL DISCUSSION III**
- 16:15–17:30 **BREAK**
- 17:30 **ALL HANDS DINNER & TALK** by the Cardiometabolic Research in Society &
Culture Program

Friday, November 1, 2024

SESSION 4 OVERCOMING OBSTACLES AND KNOWLEDGE GAPS

09:00–09:15 **Session opening**

09:15–09:45 **[Title]**

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, DK

09:45–10:15 **[Title]**

Stinus Lingreen, PhD, Member of Danish Parliament, DK

10:15–10:30 **BREAK**

10:30–11:00 **[Title]**

Lars Bo Nielsen, Director General, Danish Medicines Agency, DK

11:00–11:30 **[Title]**

Trine Bartholdy, Chief Innovation Officer, BII, DK

11:30–12:00 **PANEL DISCUSSION IV**

12:30 **CONCLUDING REMARKS – LUNCH & DEPARTURE**

Organizers: The CBMR Innovation Team

Christoffer Clemmensen – Innovation Lead, Group Leader

Kei Sakamoto – Vice Executive Director, Group Leader

Zach Gerhart-Hines – Group Leader

Thue W. Schwartz – Group Leader

Thomas Frimurer – Head of Computational Chemistry Unit

Imke Tiessen – Innovation Coordinator

<https://cbmr.ku.dk/translation/>